

Company registration number: 587076

Tullamore Primary Care Pharmacy Limited

Unaudited abridged financial statements

for the financial year ended 31 July 2025

Tullamore Primary Care Pharmacy Limited

Contents

	Page
Directors responsibilities statement	1
Balance sheet	2 - 3
Notes to the abridged financial statements	4 - 11

Tullamore Primary Care Pharmacy Limited

Directors responsibilities statement

These abridged financial statements have been extracted, pursuant to section 353 of the Companies Act 2014, from the statutory financial statements prepared under section 290 of that Act. The following is the Directors Responsibilities Statement accompanying those financial statements.


The directors are responsible for preparing the directors report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under the law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgments and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and directors report comply with the They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.


.....
Conor Morrissey
Director


.....
Sandra Morrissey
Director

Date 10th Feb 2015

Date:.....10th Feb 2015

Tullamore Primary Care Pharmacy Limited

Balance sheet as at 31 July 2025

		2025		2024	
	Note	€	€	€	€
Fixed assets					
Tangible assets	6	214,665		146,239	
			214,665		146,239
Current assets					
Stocks	7	195,000		192,147	
Debtors	8	198,840		161,278	
Cash at bank and in hand		195,169		542,450	
		<u>589,009</u>		<u>895,875</u>	
Creditors: amounts falling due within one year	9	<u>(196,089)</u>		<u>(238,874)</u>	
Net current assets			<u>392,920</u>		<u>657,001</u>
Total assets less current liabilities			<u>607,585</u>		<u>803,240</u>
Creditors: amounts falling due after more than one year			(55,038)		-
Net assets			<u><u>552,547</u></u>		<u><u>803,240</u></u>
Capital and reserves					
Called up share capital presented as equity			100		100
Profit and loss account			<u>552,447</u>		<u>803,140</u>
Shareholder funds			<u><u>552,547</u></u>		<u><u>803,240</u></u>

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

The notes on pages 4 to 11 form part of these abridged financial statements.

Tullamore Primary Care Pharmacy Limited

Balance sheet as at 31 July 2025

We, as directors of Tullamore Primary Care Pharmacy Limited state that:

- the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014;
- the company is availing itself of the exemption on the grounds that the conditions specified in section 359 of the Companies Act 2014 are satisfied;
- the shareholder of the company have not served a notice on the company under section 334(1) of the Companies Act 2014 in accordance with section 334(2);
- We acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of Companies Act 2014 relating to financial statements so far as they are applicable to the company; and
- the company has relied on the specified exemption contained in section 352 of the Companies Act 2014; has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 of the Companies Act 2014.

These abridged financial statements were approved by the board of directors on 10/2/2026 and signed on behalf of the board by:

.....
Conor Morrissey
Director

.....
Sandra Morrissey
Director

The notes on pages 4 to 11 form part of these abridged financial statements.

Tullamore Primary Care Pharmacy Limited

Notes to the abridged financial statements Financial year ended 31 July 2025

1. Accounting policies and measurement bases

Basis of preparation

The financial statements have been prepared on the going concern basis, under the historical cost convention and comply with the financial reporting standards of the Financial Reporting Council including FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102") as adapted by Section 1A of FRS 102 and the Companies Act 2014.

The financial statements are prepared in Euro, which is the functional currency of the entity.

Turnover

Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer, usually on despatch of the goods; the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

Taxation

The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in the statement of comprehensive income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively.

Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.

Operating leases

Lease payments are recognised as an expense over the lease term on a straight-line basis. The aggregate benefit of lease incentives is recognised as a reduction to expense over the lease term, on a straight-line basis.

Tullamore Primary Care Pharmacy Limited

Notes to the abridged financial statements (continued) Financial year ended 31 July 2025

Tangible assets

Tangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated depreciation and impairment losses.

Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in capital and reserves, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in capital and reserves in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in capital and reserves in respect of that asset, the excess shall be recognised in profit or loss.

Depreciation

Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

Long leasehold property	4 %	Straight line
Fittings fixtures and equipment	15 %	Straight line
Motor Vehicle	20%	Straight line

If there is an indication that there has been a significant change in depreciation rate, useful life or residual value of tangible assets, the depreciation is revised prospectively to reflect the new estimates.

Stocks

Stock is valued at the lower of cost and net realisable value. In the case of finished goods and work-in-progress, cost is defined as the aggregate cost of raw material, direct labour and attributable proportion of direct production overheads based on a normal level of activity. Net realisable value is based on normal selling price, less further costs expected to be incurred to completion and all costs to be incurred in marketing, selling and distributing.

Tullamore Primary Care Pharmacy Limited

Notes to the abridged financial statements (continued) Financial year ended 31 July 2025

Trade Debtors

Trade and other debtors are recognised initially at transaction price (including transaction costs) unless a financing arrangement exists in which case they are measured at the present value future receipts discounted at a market rate. Subsequently these are measured at amortised cost less any provision for impairment. A provision for impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of receivables. The amount of the provision is the difference between the assets carrying amount and the present value of estimated future cash flows, discounted at the effective interest rate. All movements in the level of the provision required are recognised in the profit and loss.

Dividends are recognised in the financial statements when payment has been made.

Cash at bank and on hand

Cash at bank and on hand include cash on hand, demand deposits and other term highly liquid investments regardless of maturity. Bank overdrafts are shown within borrowings in current liabilities on the statement of financial position.

Creditors and accruals

Creditors and accruals are classified as current liabilities if payment is due within one year or less. If not, they are presented as non current liabilities. Trade payables are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Share capital

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new ordinary shares or options are shown in equity as a deduction, net of tax, from the proceeds.

Related party transactions

The company discloses transactions with related parties which are not wholly owned within the same group.

2. Operating profit

Operating profit is stated after charging/(crediting):

	2025	2024
	€	€
Depreciation of tangible assets	29,515	34,386

Tullamore Primary Care Pharmacy Limited

**Notes to the abridged financial statements (continued)
Financial year ended 31 July 2025**

3. Staff costs

The average number of persons employed by the company during the financial year, including the directors was 7 (2024: 6).

	Year ending 2025	Year ending 2024
	€	€
Wages and salaries	425,785	304,866
Employer Prsi Contributions	31,140	21,750
Pension Contributions	28,039	2,651
	484,964	329,267
	484,964	329,267

4. Directors remuneration

The directors aggregate remuneration was as follows:

	2025	2024
	€	€
Emoluments in respect of qualifying services	138,774	104,712
Pension contributions to defined contribution plans in respect of qualifying services	28,039	2,651
	166,813	107,363
	166,813	107,363

5. Appropriations of profit and loss account

	2025	2024
	€	€
At the start of the financial year	803,140	490,588
(Loss)/profit for the financial year	(250,693)	312,552
	552,447	803,140
At the end of the financial year	552,447	803,140

Tullamore Primary Care Pharmacy Limited

Notes to the abridged financial statements (continued)
Financial year ended 31 July 2025

6. Tangible assets	Long leasehold property	Fixtures, fittings and equipment	Motor Vehicle	Total
	€	€	€	€
Cost				
At 1 August 2024	170,000	183,909	-	353,909
Additions	-	551	97,390	97,941
At 31 July 2025	<u>170,000</u>	<u>184,460</u>	<u>97,390</u>	<u>451,850</u>
Depreciation				
At 1 August 2024	43,200	164,470	-	207,670
Charge for the financial year	6,800	12,977	9,738	29,515
At 31 July 2025	<u>50,000</u>	<u>177,447</u>	<u>9,738</u>	<u>237,185</u>
Carrying amount				
At 31 July 2025	<u>120,000</u>	<u>7,013</u>	<u>87,652</u>	<u>214,665</u>
At 31 July 2024	<u>126,800</u>	<u>19,439</u>	<u>-</u>	<u>146,239</u>

Included in Fixed Assets is a motor vehicle subject to hire purchase finance.

7. Stocks	2025	2024
	€	€
Finished goods and goods for resale	<u>195,000</u>	<u>192,147</u>

8. Debtors	2025	2024
	€	€
Trade debtors	107,633	104,740
Other debtors	66,730	41,538
Prepayments	24,477	15,000
	<u>198,840</u>	<u>161,278</u>

Tullamore Primary Care Pharmacy Limited

Notes to the abridged financial statements (continued)
Financial year ended 31 July 2025

9. Creditors: amounts falling due within one year

	2025	2024
	€	€
Trade creditors	98,882	162,848
Amounts owed to group undertakings	-	18,702
Obligations under Hire Purchase Agreements	19,515	-
Directors Current Account	3,075	3,075
PAYE and social welfare	10,116	9,208
VAT	1,240	-
Accruals	63,261	45,041
	<u>196,089</u>	<u>238,874</u>

10. Events after the end of the reporting period

There have been no significant events affecting the company since the year end.

Tullamore Primary Care Pharmacy Limited

**Notes to the abridged financial statements (continued)
Financial year ended 31 July 2025**

11. Directors transactions

During the financial year the company entered into the following arrangements relating to loans, quasi-loans and credit transactions:

	2025	2024
	€	€
At the start of the financial year	3,075	-
Advances made during the financial year	-	-
Amounts repaid during the financial year	-	(3,075)
At the end of the financial year	3,075	3,075

Name of director or other person

Rory Moore

	2025	2024
	€	€
At the start of the financial year	-	-
Amounts repaid during the financial year	-	-
At the end of the financial year	-	-

Mr, Moore resigned as company director on 24th September 2024.

Name of director or other person

Sandra Morrissey

	2025	2024
	€	€
At the start of the financial year	3,075	-
Advances made during the financial year	-	-
Amounts repaid during the financial year	-	(3,075)
At the end of the financial year	3,075	(3,075)

The above is a loan from the director to the company and is interest free and repayable on demand.

13. Controlling party

The company is a 100% subsidiary of Streamvale Pharma Limited a company incorporated in Ireland.

14. Approval of financial statements

The board of directors approved these abridged financial statements for issue on.....

10/2/2025